Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (627)	3/17/2005 2:18:28 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 946

>> correct, but corporate cultures are slow to change. it's been my experience that slimeballs are replaced by slimeballs. << The Rosenwald model was "float something". It could have (as was most frequent) been crap, recognized crap. BLSI/Greenwis(c)h and VIMRx come to mind. But it could have been the next miracle drug, as well. The business model was "have some stupid guys support our research, while we bait and switch until we find an important, new medicine". So......... slimeballs or not (and, clearly, this CEO is a Mr. Slimeball Supreme), they've reached market with one valuable anti-cancer, and the pipe has been filled with big-science shots on goal. I agree with Sam. For a number of reasons, including the BIGGIE, insider buying here is not a Genta-like signal. The biggie? There's pipe at CTIC, whereas there was none at GNTA. Add that Rosenwald owned nearly 50% of Genta come crunch time........ that a well-timed head fake would mean bigger bucks. Maybe he's grown lazy and spoiled, don't know... been out of contact for too long (lazy, spoiled)..... but Max Link is off-scale bright. Believe that PGS's voiced skepticism serves us all, however.